Status:
COMPLETED
Empagliflozin in Treatment of Peripheral Diabetic Neuropathy
Lead Sponsor:
Tanta University
Conditions:
Diabetic Neuropathy Peripheral
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
PHASE2
Brief Summary
The aim of the study is to investigate the possible protective effect of empagliflozin in patients with type 2 diabetes mellitus with diabetic peripheral neuropathy and not on SGLT2 inhibitors treatme...
Eligibility Criteria
Inclusion
- Patients with type 2 diabetes mellitus (Hba1c 7 %- 9%). Patients receiving dipeptidyl peptidase-4 inhibitors, metformin ± basal insulin.
- Patients with peripheral neuropathy and not on SGLT2 inhibitor treatment. Patients aged between 18 years old to 65 years old.
Exclusion
- Breastfeeding female.
- Pregnant female.
- Estimated Glomerular Filtration Rate less than 45 mL/minute/1.73 m2.
- Patients with type 1 diabetes mellitus.
- Patients with diabetic ketoacidosis.
- Patients with urinary tract infections.
- Dehydrated patients till normalized.
- Lower limb amputation patients.
- SGLT2 inhibitors hypersensitivity.
- Severe hepatic patients.
- Patients on neuroprotective drugs.
Key Trial Info
Start Date :
January 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 3 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05977465
Start Date
January 20 2022
End Date
August 3 2023
Last Update
November 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of pharmacy
Tanta, Egypt, 31111